ANIP Q1 2020 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q1 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$50M-5.9% YoY

Gross Profit

$28M56.2% margin

Operating Income

-$8M-15.8% margin

Net Income

-$7M-14.1% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+3.8%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

-$56M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$482M

Total Liabilities

$281M

Stockholders' Equity

$201M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$53M	-5.9%
Gross Profit	$28M	$38M	-26.7%
Operating Income	-$8M	$4M	-278.1%
Net Income	-$7M	$440,000	-1693.4%

Revenue Segments

Unapproved Products

$4M100%

Geographic Segments

United States

$48M97%

Canada

$2M3%